Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients.

AIDS. 1999 May 28;13(8):883-90. Unique Identifier : AIDSLINE MED/99297578
Mastroianni CM; Lichtner M; Mengoni F; D'Agostino C; Forcina G; d'Ettorre G; Santopadre P; Vullo V; Department of Infectious and Tropical Diseases, La Sapienza; University of Rome, Italy. vullo@caspur.it

Abstract: OBJECTIVE: To investigate the effect of highly active antiretroviral treatment (HAART) on neutrophil and monocyte function in patients with moderately advanced HIV-1 infection. DESIGN: Eighteen HIV-1-infected patients with CD4 T cell counts below 350/microl, no concomitant active infection, and no previous use of protease inhibitors were treated with indinavir or ritonavir and two reverse-transcriptase inhibitors and were followed up for 9 months. Ten age- and sex-matched healthy subjects were included as controls. METHODS: The functional activity of neutrophils and monocytes was measured by assessing chemotaxis towards a bacterial peptide, killing activity against Candida albicans, and oxidative burst as measured by chemiluminescence production. RESULTS: Neutrophils and monocytes from the treatment group exhibited a significantly diminished baseline chemotactic and fungicidal activity compared with healthy controls (P < 0.001). After starting HAART, there was a significant improvement in chemotaxis and fungicidal activity of phagocytic cells (P < 0.001). Values of chemotaxis reached normal ranges in 13 out of 18 patients (72%) for neutrophils and eight out of 18 (44%) for monocytes, whereas phagocyte killing was rarely restored to normal values (3/18 cases for monocytes and 0/18 for neutrophils). The administration of HAART was also associated with significantly increased phagocyte chemiluminescence production in response to phorbol-12-myristate 13-acetate or opsonized C. albicans (P < 0.01). CONCLUSION: The functional improvement of two critical components of innate antimicrobial immunity, such as neutrophils and monocytes, may contribute to the improved cell-mediated immune responses against opportunistic infections in HAART-treated patients.
Keywords: CLINICAL TRIAL JOURNAL ARTICLE Adult Aged Anti-HIV Agents/*THERAPEUTIC USE Candida albicans/IMMUNOLOGY Chemiluminescence Chemotaxis, Leukocyte Drug Therapy, Combination Female Human HIV Infections/*DRUG THERAPY/IMMUNOLOGY HIV Protease Inhibitors/THERAPEUTIC USE *HIV-1 Male Middle Age Monocytes/*IMMUNOLOGY Neutrophils/*IMMUNOLOGY Phagocytosis Prospective Studies Respiratory Burst Reverse Transcriptase Inhibitors/THERAPEUTIC USE Support, Non-U.S. Gov'tKWDclinicaltrialjournalarticleadultagedanti-hivagents/KWDtherapeuticusecandidaalbicans/immunologychemiluminescencechemotaxis,leukocytedrugtherapy,combinationfemalehumanhivinfections/KWDdrugtherapy/immunologyhivproteaseinhibitors/therapeuticuseKWDhiv-1malemiddleagemonocytes/KWDimmunologyneutrophils/KWDimmunologyphagocytosisprospectivestudiesrespiratoryburstreversetranscriptaseinhibitors/therapeuticusesupport,non-uKWDsKWDgov't
991130
A99B1120

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .